Anteris Technologies initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Ross Osborn initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $9 price target Anteris is a clinical-stage structural heart company discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis, the analyst tells investors in a research note. Cantor holds a favorable view of the estimated $7.1B transcatheter aortic valve replacement aortic stenosis and valve-in-valve markets and believes Anteris’s DurAVR technology is differentiated from competitors and should serve to drive fast adoption.